Copertina

Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jens Grueger, Vaidyanathan Srikant
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence
di: Gorana Capkun, et al.
Pubblicazione: (2025)

Real‐World Evidence in Regulatory Decision Making: Time for Evidence Integration
di: Rebecca A. Miksad
Pubblicazione: (2024)

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
di: Gianmario Candore, et al.
Pubblicazione: (2025)

The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities
di: Matthew M. Abernathy, et al.
Pubblicazione: (2024)

Correction to “Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing”
Pubblicazione: (2025)

The Use of Real‐World Evidence for Regulatory Decisions in China
di: Jiayue Xu, et al.
Pubblicazione: (2024)

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective
di: Jie Chen, et al.
Pubblicazione: (2025)

Planning Post‐Launch Evidence Generation: Lessons From France, England and Spain
di: Seamus Kent, et al.
Pubblicazione: (2025)

Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review
di: Marieke S. Jansen, et al.
Pubblicazione: (2024)

Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety
di: Yow‐Ming C. Wang, et al.
Pubblicazione: (2026)

Emulating Comparative Oncology Trials With Real‐World Evidence Studies ( ENCORE ): Process Development and Methodological Considerations for Oncology Real‐World Data
di: Janick Weberpals, et al.
Pubblicazione: (2026)

US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
di: Kimberly A. Smith, et al.
Pubblicazione: (2025)

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies
di: Sonia Zebachi, et al.
Pubblicazione: (2025)

Advancing Principled Pharmacoepidemiologic Research to Support Regulatory and Healthcare Decision Making: The Era of Real‐World Evidence
di: Rohini K. Hernandez, et al.
Pubblicazione: (2025)

The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency
di: Elodie Baumfeld Andre, et al.
Pubblicazione: (2024)

Real‐World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020–2022
di: Gabriel K. Innes, et al.
Pubblicazione: (2025)

Regulation of Real‐World Evidence in Rare Diseases in the MENA Region: A Review of Current Guidelines Compared to Global Frameworks
di: Marwa Muhammed Abdeljawad, et al.
Pubblicazione: (2026)

Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
di: Nisha Sharma, et al.
Pubblicazione: (2024)

Clinical Evidence 2030
di: Peter Arlett, et al.
Pubblicazione: (2025)

Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
di: Sarah K. Emond, et al.
Pubblicazione: (2025)

Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data
di: Tomoyuki Enokiya, et al.
Pubblicazione: (2026)

Correction to Beyond MABEL : An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute ( HESI ) Immuno‐Safety Technical Committee ( ITC )
Pubblicazione: (2024)

Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective
di: Celine M. Laffont, et al.
Pubblicazione: (2025)

Reply to “Translational Modeling as a Tool to Evaluate the Effectiveness of Nalmefene in a Community Setting: A Critical Perspective”
di: Zhihua Li, et al.
Pubblicazione: (2025)

A Fast Path from Innovation to Safe and Effective Medicines
di: Peter Arlett, et al.
Pubblicazione: (2025)

Evidence Generation for Drugs and Biological Products isn't Magic or Myth
di: John Concato, et al.
Pubblicazione: (2025)

Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
di: Wenqi Dong, et al.
Pubblicazione: (2025)

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting
di: Yoomi Park, et al.
Pubblicazione: (2026)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
di: Janne T. Backman
Pubblicazione: (2025)

Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC : A Norwegian Population‐Based Cohort Study
di: Simon Boge Brant, et al.
Pubblicazione: (2025)

Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction
di: Amita Datta‐Mannan, et al.
Pubblicazione: (2024)

Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline
di: Akihiro Hirakawa, et al.
Pubblicazione: (2024)

The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence‐Based Medicine
di: Charles Khouri, et al.
Pubblicazione: (2025)

Assessment of Efficacy Evidence for Approvals of Novel Drugs in China Between 2018 and 2022
di: Yang Xu, et al.
Pubblicazione: (2024)

Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines
di: Karthik Venkatakrishnan, et al.
Pubblicazione: (2025)

Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens
di: Sung‐Chun Tang, et al.
Pubblicazione: (2025)

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data
di: Kaisa Litonius, et al.
Pubblicazione: (2024)

Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
di: Rishi J. Desai, et al.
Pubblicazione: (2025)

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov
di: Lars Masanneck, et al.
Pubblicazione: (2024)

Corrections to “Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions”
Pubblicazione: (2024)